Potentially huge legal issues are hovering over Kenvue. But Kimberly-Clark, which agreed to buy it for $40 billion, appears ...

Shares in data analytics software developer Palantir tumble even as the company tops analysts' earnings estimates.

Kimberly-Clark plans a $48.7B Kenvue acquisition to drive growth and synergies. Learn the deal's risks, impacts, and KMB's ...

Despite a headline beat and decent revenue forecast, the poor reaction to the update from AI and data analytics darling ...

In this piece, we will look at the stocks Jim Cramer discussed.

OpenAI strikes cloud computing deal with Amazon, Palantir CEO touts strong third-quarter results, Trump threatens to cut NYC ...

Consumer giant Kimberly-Clark has agreed to buy Kenvue, the parent company of embattled brand Tylenol, for nearly $49 billion. But what does this mean for consumers and shareholders?

Under the agreement, each Kenvue Inc. (NYSE:KVUE) shareholder would receive $3.5 per share in cash as well as 0.14625 ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a huge consumer ...

The consumer health and wellness giants are both Dividend Kings, with more than 50 years of consecutive annual payout ...

Palantir Technologies, which came into the day with a stunning 165% gain for the year so far, rose another 3.3%. Traders ...